JP2019517778A - 細胞溶解及び核酸増幅のためのプロセス - Google Patents
細胞溶解及び核酸増幅のためのプロセス Download PDFInfo
- Publication number
- JP2019517778A JP2019517778A JP2018552671A JP2018552671A JP2019517778A JP 2019517778 A JP2019517778 A JP 2019517778A JP 2018552671 A JP2018552671 A JP 2018552671A JP 2018552671 A JP2018552671 A JP 2018552671A JP 2019517778 A JP2019517778 A JP 2019517778A
- Authority
- JP
- Japan
- Prior art keywords
- aqueous composition
- volume
- nucleic acid
- lysis buffer
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 158
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 118
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 116
- 230000003321 amplification Effects 0.000 title claims abstract description 109
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 109
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 109
- 230000008569 process Effects 0.000 title claims abstract description 49
- 230000006037 cell lysis Effects 0.000 title description 7
- 239000000203 mixture Substances 0.000 claims abstract description 219
- 239000012139 lysis buffer Substances 0.000 claims abstract description 118
- 238000006243 chemical reaction Methods 0.000 claims abstract description 77
- 244000005700 microbiome Species 0.000 claims abstract description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 60
- 238000009825 accumulation Methods 0.000 claims abstract description 56
- 235000015097 nutrients Nutrition 0.000 claims abstract description 30
- 238000002156 mixing Methods 0.000 claims abstract description 28
- 239000000126 substance Substances 0.000 claims abstract description 26
- 230000009089 cytolysis Effects 0.000 claims abstract description 24
- 239000002198 insoluble material Substances 0.000 claims abstract description 24
- 230000001404 mediated effect Effects 0.000 claims abstract description 24
- 238000009472 formulation Methods 0.000 claims abstract description 15
- 239000008363 phosphate buffer Substances 0.000 claims abstract description 8
- 239000000872 buffer Substances 0.000 claims description 65
- 239000002245 particle Substances 0.000 claims description 36
- 150000001768 cations Chemical class 0.000 claims description 34
- 239000002738 chelating agent Substances 0.000 claims description 31
- 239000003153 chemical reaction reagent Substances 0.000 claims description 26
- 238000007397 LAMP assay Methods 0.000 claims description 25
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 24
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 24
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims description 23
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 23
- -1 iron ion Chemical class 0.000 claims description 22
- 239000002105 nanoparticle Substances 0.000 claims description 21
- 239000002736 nonionic surfactant Substances 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 19
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 18
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 claims description 18
- 238000003752 polymerase chain reaction Methods 0.000 claims description 18
- 229910001928 zirconium oxide Inorganic materials 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 17
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 17
- 239000004094 surface-active agent Substances 0.000 claims description 13
- 239000006185 dispersion Substances 0.000 claims description 11
- 239000008367 deionised water Substances 0.000 claims description 10
- 229910021641 deionized water Inorganic materials 0.000 claims description 10
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 10
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 10
- 238000004090 dissolution Methods 0.000 claims description 9
- 229910052742 iron Inorganic materials 0.000 claims description 9
- 239000011777 magnesium Substances 0.000 claims description 9
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 9
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 9
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- 229910052749 magnesium Inorganic materials 0.000 claims description 8
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 8
- PJWWRFATQTVXHA-UHFFFAOYSA-N Cyclohexylaminopropanesulfonic acid Chemical compound OS(=O)(=O)CCCNC1CCCCC1 PJWWRFATQTVXHA-UHFFFAOYSA-N 0.000 claims description 5
- 239000012943 hotmelt Substances 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 claims description 4
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 238000005382 thermal cycling Methods 0.000 claims description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 3
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 239000000523 sample Substances 0.000 description 52
- 239000002609 medium Substances 0.000 description 39
- 108020004414 DNA Proteins 0.000 description 23
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 23
- 241000607142 Salmonella Species 0.000 description 21
- 241000894007 species Species 0.000 description 21
- 238000001514 detection method Methods 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 18
- 241000589876 Campylobacter Species 0.000 description 15
- 241000588724 Escherichia coli Species 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 239000000975 dye Substances 0.000 description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 13
- 238000006073 displacement reaction Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 11
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 11
- 235000013305 food Nutrition 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 239000006166 lysate Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 239000001888 Peptone Substances 0.000 description 7
- 108010080698 Peptones Proteins 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 229910001447 ferric ion Inorganic materials 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 235000019319 peptone Nutrition 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 241001138501 Salmonella enterica Species 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000006820 DNA synthesis Effects 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000011901 isothermal amplification Methods 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 235000010633 broth Nutrition 0.000 description 4
- OBRMNDMBJQTZHV-UHFFFAOYSA-N cresol red Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 OBRMNDMBJQTZHV-UHFFFAOYSA-N 0.000 description 4
- 230000001351 cycling effect Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 229910001414 potassium ion Inorganic materials 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- RCITVHFNWJIDNA-UHFFFAOYSA-K [NH4+].[NH4+].[NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O Chemical compound [NH4+].[NH4+].[NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O RCITVHFNWJIDNA-UHFFFAOYSA-K 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 3
- URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- INEWUCPYEUEQTN-UHFFFAOYSA-N 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CNC1CCCCC1 INEWUCPYEUEQTN-UHFFFAOYSA-N 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 241001225321 Aspergillus fumigatus Species 0.000 description 2
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 2
- 239000008001 CAPS buffer Substances 0.000 description 2
- 241000589875 Campylobacter jejuni Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000223221 Fusarium oxysporum Species 0.000 description 2
- 241000427940 Fusarium solani Species 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CVRXLMUYFMERMJ-UHFFFAOYSA-N N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine Chemical compound C=1C=CC=NC=1CN(CC=1N=CC=CC=1)CCN(CC=1N=CC=CC=1)CC1=CC=CC=N1 CVRXLMUYFMERMJ-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000235645 Pichia kudriavzevii Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000193985 Streptococcus agalactiae Species 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229910052751 metal Chemical class 0.000 description 2
- 239000002184 metal Chemical class 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000013026 undiluted sample Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228193 Aspergillus clavatus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000228257 Aspergillus sp. Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241001135265 Cronobacter sakazakii Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241001333951 Escherichia coli O157 Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 241000006782 Fusarium chlamydosporum Species 0.000 description 1
- 241000827781 Geobacillus sp. Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000186780 Listeria ivanovii Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 241001084338 Listeria sp. Species 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 102000004523 Sulfate Adenylyltransferase Human genes 0.000 description 1
- 108010022348 Sulfate adenylyltransferase Proteins 0.000 description 1
- 239000007994 TES buffer Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 229920004920 Triton N-60 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004891 Triton X-101 Polymers 0.000 description 1
- 229920004892 Triton X-102 Polymers 0.000 description 1
- 229920004929 Triton X-114 Polymers 0.000 description 1
- 229920004923 Triton X-15 Polymers 0.000 description 1
- 229920004893 Triton X-165 Polymers 0.000 description 1
- 229920004894 Triton X-305 Polymers 0.000 description 1
- 229920004896 Triton X-405 Polymers 0.000 description 1
- 229920004897 Triton X-45 Polymers 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 241000607284 Vibrio sp. Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- FRHBOQMZUOWXQL-UHFFFAOYSA-K azane;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+) Chemical compound N.[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-K 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XZTWHWHGBBCSMX-UHFFFAOYSA-J dimagnesium;phosphonato phosphate Chemical compound [Mg+2].[Mg+2].[O-]P([O-])(=O)OP([O-])([O-])=O XZTWHWHGBBCSMX-UHFFFAOYSA-J 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
- 238000011549 displacement method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000000396 iron Nutrition 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 235000020989 red meat Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- AUIINJJXRXMPGT-UHFFFAOYSA-K trisodium 3-hydroxy-4-[(2-hydroxy-4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].[Na+].Oc1cc(c2ccccc2c1N=Nc1c(O)c(cc2cc(ccc12)S([O-])(=O)=O)S([O-])(=O)=O)S([O-])(=O)=O AUIINJJXRXMPGT-UHFFFAOYSA-K 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
本出願は、2016年4月8日に出願された米国仮特許出願第62/319,876号の優先権を主張するものであり、この開示内容は、その全容が参照により本明細書に組み込まれる。
実施形態Aは核酸増幅法であって、
試料を、水溶性リン酸イオンを実質的に含まず第1の緩衝液を含む栄養培地と接触させることによって、集積培養物を形成することと、
集積培養物を、ある時間、標的微生物の生育を促進する温度に維持することと、
集積培養物を維持した後に、第1の体積の集積培養物を第2の体積の溶解緩衝液と混合し、第3の体積の水性組成物を形成することにより、水性組成物を形成することであって、
第1の体積の集積培養物を第2の体積の溶解緩衝液と混合することが、無希釈の第1の体積の集積培養物を第2の体積の溶解緩衝液と混合することを含み、
溶解緩衝液が水溶性リン酸イオンを実質的に含まず、第2の緩衝液を含み、
溶解緩衝液が有機多価陽イオンキレート試薬を含み、有機多価陽イオンキレート試薬が、三価鉄に対して104.2以上の第1の結合定数と、マグネシウムに対して103.8未満の第2の結合定数とを有し、第1の結合定数及び第2の結合定数が、20℃の脱イオン水中、pH8.45で測定されたものであり、
溶解緩衝液は、25℃でpHが8.6超であり、
水性組成物は、25℃でpHが約8.45〜8.85であり、
水性組成物中の第1の緩衝液と第2の緩衝液との合算した濃度が、少なくとも約15mMであり、
第1の体積の第2の体積に対する比が3:1以上であり、第2の体積の第3の体積に対する比が1:4以下である、水性組成物を形成することと、
水性組成物を、ポリメラーゼ媒介核酸増幅反応を阻害する物質を封鎖する有効量の水不溶性材料と接触させることと、
水性組成物を熱溶解プロセスに付すことと、
水性組成物を熱溶解プロセスに付した後に、水性組成物の一部分を核酸増幅プロセスに付すことと、
を含む、方法である。
試料を、リン酸緩衝液構成成分を含まない配合を有し、第1の緩衝液を含む栄養培地と接触させることによって、集積培養物を形成することと、
集積培養物を、ある時間、標的微生物の生育を促進する温度に維持することと、
集積培養物を維持した後に、第1の体積の集積培養物を第2の体積の溶解緩衝液と混合し、第3の体積の水性組成物を形成することにより、水性組成物を形成することであって、
第1の体積の集積培養物を第2の体積の溶解緩衝液と混合することが、無希釈の第1の体積の集積培養物を第2の体積の溶解緩衝液と混合することを含み、
溶解緩衝液が第2の緩衝液を含み、
溶解緩衝液が有機多価陽イオンキレート試薬を含み、有機多価陽イオンキレート試薬が、三価鉄に対して104.2以上の第1の結合定数と、マグネシウムに対して103.8未満の第2の結合定数とを有し、第1の結合定数及び第2の結合定数が、20℃の脱イオン水中、pH8.45で測定されたものであり、
溶解緩衝液は、25℃でpHが8.6超であり、
水性組成物は、25℃でpHが約8.45〜8.85であり、
水性組成物中の第1の緩衝液と第2の緩衝液との合算した濃度が、少なくとも約15mMであり、
第1の体積の第2の体積に対する比が3:1以上であり、第2の体積の第3の体積に対する比が1:4以下である、水性組成物を形成することと、
水性組成物を、ポリメラーゼ媒介核酸増幅反応を阻害する物質を封鎖する有効量の水不溶性材料と接触させることと、
水性組成物を熱溶解プロセスに付すことと、
水性組成物を熱溶解プロセスに付した後に、水性組成物の一部分を核酸増幅プロセスに付すことと、
を含む、方法である。
水性組成物を熱溶解プロセスに付した後、かつ水性組成物の一部分を核酸増幅プロセスに付す前に、水性組成物の一部分を用い、核酸増幅用の脱水された試薬を再水和すること、を更に含む、請求項A〜Qのいずれか1つに記載の方法である。
ポリメラーゼ媒介核酸増幅反応を阻害する物質を封鎖する水不溶性材料と、
有機多価陽イオンキレート試薬と、
少なくとも1種のノニオン性界面活性剤と、
三価鉄と、
ポリメラーゼ活性を促進する試薬と、
緩衝液と、
水と、
を含み、
1mM未満のリン酸又はその塩を含み、
25℃でpHが約9.8〜10.5(両端の値を含む)である、溶解緩衝液である。
Claims (20)
- 核酸増幅法であって、
試料を、リン酸緩衝液構成成分を含まない配合を有し、第1の緩衝液を含む栄養培地と接触させることによって、集積培養物を形成することと、
前記集積培養物を、ある時間、標的微生物の生育を促進する温度に維持することと、
前記集積培養物を維持した後に、第1の体積の前記集積培養物を第2の体積の溶解緩衝液と混合し、第3の体積の水性組成物を形成することにより、前記水性組成物を形成することであって、
前記第1の体積の前記集積培養物を前記第2の体積の前記溶解緩衝液と混合することが、無希釈の第1の体積の前記集積培養物を前記第2の体積の前記溶解緩衝液と混合することを含み、
前記溶解緩衝液が第2の緩衝液を含み、
前記溶解緩衝液が有機多価陽イオンキレート試薬を含み、前記有機多価陽イオンキレート試薬が、三価鉄に対して104.2以上の第1の結合定数と、マグネシウムに対して103.8未満の第2の結合定数とを有し、前記第1の結合定数及び前記第2の結合定数が、20℃の脱イオン水中、pH8.45で測定されたものであり、
前記溶解緩衝液は、25℃でpHが8.6超であり、
前記水性組成物は、25℃でpHが約8.45〜8.85であり、
前記水性組成物中の前記第1の緩衝液と前記第2の緩衝液との合算した濃度が、少なくとも約15mMであり、
前記第1の体積の前記第2の体積に対する比が3:1以上であり、前記第2の体積の前記第3の体積に対する比が1:4以下である、前記水性組成物を形成することと、
前記水性組成物を、ポリメラーゼ媒介核酸増幅反応を阻害する物質を封鎖する有効量の水不溶性材料と接触させることと、
前記水性組成物を熱溶解プロセスに付すことと、
前記水性組成物を前記熱溶解プロセスに付した後に、前記水性組成物の一部分を核酸増幅プロセスに付すことと、
を含む、方法。 - 前記溶解緩衝液が三価鉄を更に含む、請求項1に記載の方法。
- 前記溶解緩衝液が、ナノ粒子分散安定剤、親水性親油性バランスが約11〜約16であるノニオン性界面活性剤、ポリビニルピロリドン、硫酸マグネシウム七水和物、フッ素系界面活性剤、指示染料、及びこれらの試薬のうちの任意の2つ以上の組み合わせからなる群から選択される前記試薬を更に含む、請求項1又は2に記載の方法。
- 前記集積培養物をある時間維持することが、前記集積培養物を約4時間〜約24時間の間維持すること、を含む、請求項1〜3のいずれか一項に記載の方法。
- 前記第1の体積の前記第2の体積に対する前記比が5:1以上であり、前記第2の体積の前記第3の体積に対する前記比が1:6以下である、請求項1〜4のいずれか一項に記載の方法。
- 前記第1の体積の前記集積培養物を前記第2の体積の前記溶解緩衝液と混合することによって前記水性組成物を形成することが、前記水性組成物からポリメラーゼ媒介核酸増幅反応を阻害する物質を抽出する前記水不溶性材料が配置された前記水性組成物を形成することを含む、請求項1〜5のいずれか一項に記載の方法。
- 前記水不溶性材料が複数の酸化ジルコニウム粒子を含む、請求項1〜6のいずれか一項に記載の方法。
- 前記複数の酸化ジルコニウム粒子が、前記第3の体積中、約10m2/L〜約600m2/Lの表面積を有する、請求項7に記載の方法。
- 前記水性組成物の一部分を核酸増幅プロセスに付すことが、前記水性組成物の前記一部分を、ループ媒介等温増幅プロセスに付すこと、を含む、請求項1〜8のいずれか一項に記載の方法。
- 前記水性組成物の一部分を核酸増幅プロセスに付すことが、前記水性組成物の前記一部分を、熱サイクリングポリメラーゼ連鎖反応プロセスに付すこと、を含む、請求項1〜8のいずれか一項に記載の方法。
- 前記水性組成物を形成することが、前記第1の体積の前記集積培養物を前記第2の体積の前記溶解緩衝液と混合することから本質的になる、請求項1〜10のいずれか一項に記載の方法。
- 前記水性組成物を前記熱溶解プロセスに付した後、かつ前記水性組成物の前記一部分を前記核酸増幅プロセスに付す前に、前記水性組成物の前記一部分を用い、核酸増幅用の脱水された試薬を再水和すること、を更に含む、請求項1〜11のいずれか一項に記載の方法。
- ポリメラーゼ媒介核酸増幅反応を阻害する物質を封鎖する水不溶性材料と、
有機多価陽イオンキレート試薬と、
少なくとも1種のノニオン性界面活性剤と、
三価鉄と、
ポリメラーゼ活性を促進する試薬と、
N−シクロヘキシル−3−アミノプロパンスルホン酸又はその塩を含む緩衝液と、
水と、
を含み、
1mM未満のリン酸又はその塩を含み、25℃でpHが約9.8〜10.5(両端の値を含む)である、溶解緩衝液。 - 前記水不溶性材料が、複数の酸化ジルコニウム粒子、複数のヒドロキシアパタイト粒子、又はこれらの混合物を含む、請求項13に記載の溶解緩衝液。
- 前記有機多価陽イオンキレート試薬が、三価鉄イオンに対して104.2以上の結合定数と、マグネシウムイオンに対して103.8未満の結合定数とを有し、前記第1の結合定数及び前記第2の結合定数が、20℃の脱イオン水中、pH8.45で測定されたものである、請求項13又は14に記載の溶解緩衝液。
- ポリビニルピロリドン又はポリビニルポリピロリドンを更に含む、請求項13〜15のいずれか一項に記載の溶解緩衝液。
- 塩化カリウムを更に含む、請求項13〜16のいずれか一項に記載の溶解緩衝液。
- 硫酸アンモニウムを更に含む、請求項13〜17のいずれか一項に記載の溶解緩衝液。
- ナノ粒子の分散を促進する試薬を更に含む、請求項13〜18のいずれか一項に記載の溶解緩衝液。
- 前記溶解緩衝液の温度をモニターするための指示染料を更に含む、請求項13〜19のいずれか一項に記載の溶解緩衝液。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662319876P | 2016-04-08 | 2016-04-08 | |
US62/319,876 | 2016-04-08 | ||
PCT/US2017/023951 WO2017176469A1 (en) | 2016-04-08 | 2017-03-24 | Process for cell lysis and nucleic acid amplification |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019517778A true JP2019517778A (ja) | 2019-06-27 |
JP2019517778A5 JP2019517778A5 (ja) | 2020-04-30 |
JP6979409B2 JP6979409B2 (ja) | 2021-12-15 |
Family
ID=58633077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018552671A Active JP6979409B2 (ja) | 2016-04-08 | 2017-03-24 | 細胞溶解及び核酸増幅のためのプロセス |
Country Status (6)
Country | Link |
---|---|
US (1) | US11168352B2 (ja) |
EP (1) | EP3440223B1 (ja) |
JP (1) | JP6979409B2 (ja) |
CN (1) | CN109072286B (ja) |
BR (1) | BR112018069624A2 (ja) |
WO (1) | WO2017176469A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021400825A1 (en) * | 2020-12-16 | 2023-07-06 | Biofire Diagnostics, Llc | Systems, methods, and apparatuses for concentration and identification of a microorganism from blood |
EP4396374A1 (en) | 2021-09-01 | 2024-07-10 | Neogen Food Safety US HoldCo Corporation | Compositions and methods of detecting analytes |
EP4163369A1 (en) * | 2021-10-08 | 2023-04-12 | AXAGARIUS GmbH & Co. KG | Use of mixtures of polyvinylpyrrolidone and ammonium sulfate in the isolation of nucleic acids |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08149974A (ja) * | 1994-11-30 | 1996-06-11 | Q P Corp | Pcr用増菌培地 |
JPH09173065A (ja) * | 1995-09-28 | 1997-07-08 | Becton Dickinson & Co | 核酸増幅反応の阻害を減少する方法 |
US5726021A (en) * | 1994-06-16 | 1998-03-10 | Becton Dickinson And Company | Rapid and sensitive detection of antibiotic-resistant mycobacteria using oligonucleotide probes specific for ribosomal RNA precursors |
KR20090084364A (ko) * | 2008-02-01 | 2009-08-05 | 주식회사 인트론바이오테크놀로지 | 금속 이온에 의해 발생하는 pcr 저해 및 비특이 증폭을완화시키거나 막을 수 있는 에틸렌글리콜테트라아세틱 산을킬레이트제로 포함하는 pcr 반응용 조성물 |
JP2011097828A (ja) * | 2008-07-09 | 2011-05-19 | Beckman Coulter Inc | 全血試料の前処理方法及び核酸増幅方法 |
WO2011103539A1 (en) * | 2010-02-19 | 2011-08-25 | Argylla Technologies | Isolation of biomolecules from biological samples |
WO2013147043A1 (ja) * | 2012-03-29 | 2013-10-03 | 株式会社シノテスト | 核酸の検出又は定量方法及び検出又は定量用試薬キット |
WO2014072366A1 (en) * | 2012-11-07 | 2014-05-15 | Qiagen Gmbh | Method for lysing a fixed biological sample |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH056607A (ja) | 1991-06-28 | 1993-01-14 | Sony Corp | デイスクプレーヤ |
JP4241929B2 (ja) | 1996-05-22 | 2009-03-18 | ジェン―プローブ・インコーポレーテッド | Mycobacterium Kansasiiを検出するための組成物および方法 |
JP5006607B2 (ja) | 2006-09-19 | 2012-08-22 | 栄研化学株式会社 | 核酸増幅反応における阻害を回避する方法 |
US20140038174A1 (en) * | 2011-04-26 | 2014-02-06 | Longhorn Vaccines And Diagnostics, Llc | Compositions and Methods for Detecting and Identifying Nucleic Acid Sequences in Biological Samples |
EP2634254A1 (en) * | 2012-02-29 | 2013-09-04 | QIAGEN GmbH | Method for isolating nucleic acids from a food sample |
US20150225712A1 (en) | 2012-08-21 | 2015-08-13 | Qiagen Gmbh | Method for isolating nucleic acids from a formaldehyde releaser stabilized sample |
EP3189162A1 (en) | 2014-09-02 | 2017-07-12 | Pharmozyme, Inc. | Genetic detection platform |
CN105462957A (zh) * | 2014-09-30 | 2016-04-06 | 鸿慧(上海)生物科技有限公司 | 一种裂解组合物及其用途、试剂盒、利用该裂解组合物制备核酸的方法、核酸分析的方法 |
EP3594342B1 (en) | 2014-12-23 | 2021-11-03 | 3M Innovative Properties Company | Composition for reducing inhibition of nucleic acid amplification |
WO2016183012A1 (en) | 2015-05-11 | 2016-11-17 | 3M Innovative Properties Company | Composition for reducing inhibition of nucleic acid amplification |
-
2017
- 2017-03-24 US US16/087,750 patent/US11168352B2/en active Active
- 2017-03-24 CN CN201780022472.9A patent/CN109072286B/zh active Active
- 2017-03-24 BR BR112018069624A patent/BR112018069624A2/pt active Search and Examination
- 2017-03-24 JP JP2018552671A patent/JP6979409B2/ja active Active
- 2017-03-24 EP EP17719745.6A patent/EP3440223B1/en active Active
- 2017-03-24 WO PCT/US2017/023951 patent/WO2017176469A1/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5726021A (en) * | 1994-06-16 | 1998-03-10 | Becton Dickinson And Company | Rapid and sensitive detection of antibiotic-resistant mycobacteria using oligonucleotide probes specific for ribosomal RNA precursors |
JPH08149974A (ja) * | 1994-11-30 | 1996-06-11 | Q P Corp | Pcr用増菌培地 |
JPH09173065A (ja) * | 1995-09-28 | 1997-07-08 | Becton Dickinson & Co | 核酸増幅反応の阻害を減少する方法 |
KR20090084364A (ko) * | 2008-02-01 | 2009-08-05 | 주식회사 인트론바이오테크놀로지 | 금속 이온에 의해 발생하는 pcr 저해 및 비특이 증폭을완화시키거나 막을 수 있는 에틸렌글리콜테트라아세틱 산을킬레이트제로 포함하는 pcr 반응용 조성물 |
JP2011097828A (ja) * | 2008-07-09 | 2011-05-19 | Beckman Coulter Inc | 全血試料の前処理方法及び核酸増幅方法 |
WO2011103539A1 (en) * | 2010-02-19 | 2011-08-25 | Argylla Technologies | Isolation of biomolecules from biological samples |
WO2013147043A1 (ja) * | 2012-03-29 | 2013-10-03 | 株式会社シノテスト | 核酸の検出又は定量方法及び検出又は定量用試薬キット |
WO2014072366A1 (en) * | 2012-11-07 | 2014-05-15 | Qiagen Gmbh | Method for lysing a fixed biological sample |
Also Published As
Publication number | Publication date |
---|---|
CN109072286A (zh) | 2018-12-21 |
US20190112637A1 (en) | 2019-04-18 |
WO2017176469A1 (en) | 2017-10-12 |
CN109072286B (zh) | 2023-08-11 |
EP3440223B1 (en) | 2020-12-23 |
US11168352B2 (en) | 2021-11-09 |
JP6979409B2 (ja) | 2021-12-15 |
EP3440223A1 (en) | 2019-02-13 |
BR112018069624A2 (pt) | 2019-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6650944B2 (ja) | 核酸増幅の阻害を低減するための組成物 | |
JP6785249B2 (ja) | 核酸増幅の阻害を低減するための組成物 | |
JP7476466B2 (ja) | 微生物の分離及び検出 | |
US20210130873A1 (en) | Method and Kit of Detecting the Absence of Micro-Organisms | |
JP6466437B2 (ja) | 微生物を複雑な試料から単離する方法 | |
JP6979409B2 (ja) | 細胞溶解及び核酸増幅のためのプロセス | |
Papanicolas et al. | Optimisation of a propidium monoazide based method to determine the viability of microbes in faecal slurries for transplantation | |
JP6834164B2 (ja) | Pcr反応溶液の検出感度を維持する方法 | |
US9738939B2 (en) | Method for differentiating between living and dead cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200319 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200319 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210224 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210309 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210602 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210713 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211007 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211019 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211115 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6979409 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |